| 000 | 01734cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030849.0 | ||
| 008 | 130917s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.08.Ph.D.2013.Ib.P | ||
| 100 | 0 | _aIbtehal Salah Addin Abdulsaboor Ahmad | |
| 245 | 1 | 2 |
_aA pharmaceutical study on zaleplon / _cIbtehal Salah Addin Abdulsaboor Ahmad ; Supervised Ahmed Abdelbary , Omaima N. Elgazayerly , Arwa Elhagrasy |
| 246 | 1 | 5 | _aدراسة صيدلية على عقار الزاليبلون |
| 260 |
_aCairo : _bIbtehal Salah Addin Abdulsaboor Ahmad , _c2013 |
||
| 300 |
_a238P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy- Department of Pharmaceutics | ||
| 520 | _aZaleplon is a hypnotic drug used for the treatment of insomnia . It has elimination half life of 1 hour . But , it suffers from low bioavailability following oral administration using traditional dosage forms due its poor solubility and its extensive first pass metabolism . It needs to be incorporated into a dosage form that enhances its bioavailability and also be in a dosage form which sustains the release of the drug for duration of time enough to maintain sleep | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aMicroparticles | |
| 653 | 4 | _aOrally disintegrating tablets | |
| 653 | 4 | _aZaleplon | |
| 700 | 0 |
_aAhmed Abdelbary , _eSupervisor |
|
| 700 | 0 |
_aArwa Elhagrasy , _eSupervisor |
|
| 700 | 0 |
_aOmaima N. Elgazayerly , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c43536 _d43536 |
||